ArticleJCI insight2018

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Yiyi Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.